Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy before it can consider approval.

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the drug rose by more than 160% last year to reach $602 million, placing it on a ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than addressing the root cause of disease. However, cell and gene therapy (CGT) is ...

Pharma has so far been exempted from Trump's tariff blitz, which imposed a flat rate of 10% on imports from 5th April and much higher levels on countries deemed to have the greatest trade surplus with ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Pfizer was also developing a twice-daily formulation of the drug, which showed promising weight loss, but was plagued by ...

Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of ...

A regimen based on Roche's CD20xCD3 bispecific antibody Columvi has been approved in the EU as a second-line therapy for ...

Incyte's infringement lawsuit is claiming that Sun Pharma's drug infringes a US patent (No. 9,662,335) it holds on the use of ...

At Reuters Pharma USA last month, Editor in Chief Jonah Comstock caught up with John Androsavich, general manager of Gingko ...

Following the success of the Boston and European editions, the ESG in Life Sciences Summit West is bringing together senior ...

Top NHS doctor, CEO out. Across the pond, NHS England is also seeing big changes with Sir Stephen Powis announcing his plans ...